100%ige US-Zulassung in wenigen Wochen=Spottbillig
Seite 1 von 1 Neuester Beitrag: 01.02.10 11:27 | ||||
Eröffnet am: | 20.01.10 14:30 | von: Biotechmaste. | Anzahl Beiträge: | 11 |
Neuester Beitrag: | 01.02.10 11:27 | von: printus11-1 | Leser gesamt: | 9.606 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
Deshalb sollte man bei diesen kursen zugreifen .....Macht eure Hausaufgaben und seht selbst wie verdammt billig die Aktie ist .
Cipher Pharma (DND.TO)
Market Cap : 17 Mio$
Cash : 9 Mio$ <<< reicht bis zur Profitablität !!!
Kurs: 0,71 $
Shares Out : 24 M
Pipeline
http://cipherpharma.com/web/main.cfm?docID=11
Cipher secures summary judgment in the company's favour in pending patent litigation involving CIP-TRAMADOL ER
1/4/2010 7:00 AM - Canada NewsWire
http://www.stockhouse.com/tools/...Fsymbol%3DT.DND%26newsid%3D7580687
Unbedingt lesen ...
http://biotuesday.ca/2010/01/05/...-to-license-in-new-drug-this-year/
Presentation
http://cipherpharma.com/downloads/DND_Presentation_BIO_Oct2009.pdf
http://ih.advfn.com/...ol=T^DND&period=0&size=19&volume=1
http://ih.advfn.com/...=T%5EDND&period=0&size=19&volume=1
Cipher also said it would continue discussions with potential partners for licensing of the drug.
The Cipher Judgment terminates any further stay of Cipher's NDA under the applicable provisions of the Hatch-Waxman Act.
Dürfte auch hier in D bald locker über die1€-Marke gehen ...
http://quote.barchart.com/texpert.asp?sym=DND.TO
Allein die Geschäftsführer halten ca 12 Mio Aktien !!!!!!!!!!!!!!!!
http://canadianinsider.com/coReport/allTransactions.php?ticker=dnd
Sieht aus als würde Cipher wieder im grünen bereich starten .
http://finance.yahoo.com/q?s=dnd.to
Cipher ist Schuldenfrei und ist schon fast Profitabel dank Lipofen (cholesterinsenker) das schon in USA und Kanada zugelassen ist !!!
Letzte Quartalszahlen
http://finance.yahoo.com/news/...009-cnw-1063492544.html?x=0&.v=1
§ Q3 2009 Summary
§ ---------------
§ - Total revenue increased 59% to $1.1 million, compared with $0.7
§ million in Q3 2008.
§ - Continued steady growth of Lipofen(R) prescriptions.
§ - Commenced CIP-ISOTRETINOIN Phase III safety trial.
§ - A strong balance sheet at quarter end with cash of $9.3 million and
§ no debt.
"The third quarter saw us deliver a solid year-over-year increase in revenue from Lipofen(R) and enroll our first patient in the phase III safety trial for CIP-ISOTRETINOIN, reaching an important clinical milestone for this product after significant trial planning and preparation," said Larry Andrews, President and CEO of Cipher. "Patient enrollment in the CIP-ISOTRETINOIN trial is progressing well and we are also encouraged by Kowa's increased sales and promotion efforts for Lipofen(R), which should drive continued prescription growth for the product."
http://www.stockhouse.com/tools/...sp%3Fsymbol%3DT.DND%26table%3DLIST
Weitere Kursgewinne sind so gut wie sicher ...
Einfach in ruhe mal durchlesen ..
http://biotuesday.ca/2010/01/05/...-to-license-in-new-drug-this-year/
http://ih.advfn.com/...chart&s=T%5EDND&p=0&t=19&vol=1